Parameter | Percentage of group | |
---|---|---|
Drug classes | NRTI + PI | 52.5% (n = 21) |
NRTI + NNRTI | 27.5% (n = 11) | |
NRTI + NNRTI + PI | 5.0% (n = 2) | |
PI | 2.5% (n = 1) | |
NRTI | 12.5% (n = 5) | |
Therapy regimen | First line ART | 68.3% |
Second/third line therapy | 31.7% | |
Nadir (CD4+) | 275.6 ± 141.3 cells/μL | |
Duration of HAART | 9.2 ± 4.3 years |